Cargando…
Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer
Oncological use of anti-angiogenic VEGF inhibitors has been limited by the lack of informative biomarkers. Previously we reported circulating Tie2 as a vascular response biomarker for bevacizumab-treated ovarian cancer patients. Using advanced MRI and circulating biomarkers we have extended these fi...
Autores principales: | Jayson, Gordon C., Zhou, Cong, Backen, Alison, Horsley, Laura, Marti-Marti, Kalena, Shaw, Danielle, Mescallado, Nerissa, Clamp, Andrew, Saunders, Mark P., Valle, Juan W., Mullamitha, Saifee, Braun, Mike, Hasan, Jurjees, McEntee, Delyth, Simpson, Kathryn, Little, Ross A., Watson, Yvonne, Cheung, Susan, Roberts, Caleb, Ashcroft, Linda, Manoharan, Prakash, Scherer, Stefan J., del Puerto, Olivia, Jackson, Alan, O’Connor, James P. B., Parker, Geoff J. M., Dive, Caroline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220185/ https://www.ncbi.nlm.nih.gov/pubmed/30405103 http://dx.doi.org/10.1038/s41467-018-07174-1 |
Ejemplares similares
-
Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer
por: Morgan, Robert D, et al.
Publicado: (2019) -
Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study
por: Mahmood, Reem D., et al.
Publicado: (2021) -
The Impact of Changes in Service Delivery in Patients With Colorectal Cancer During the Initial Phase of the COVID-19 Pandemic
por: Kamposioras, Konstantinos, et al.
Publicado: (2021) -
Modification to Systemic Anticancer Therapy at the Start of the COVID-19 Pandemic and its Overall Impact on Survival Outcomes in Patients with Colorectal Cancer
por: Kamposioras, Konstantinos, et al.
Publicado: (2022) -
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
por: Zhou, Cong, et al.
Publicado: (2016)